Compounding Pharmacies — What They Are and Why GLP-1s Cost Less

In my last post, I shared how I got started with a GLP-1. My doctor wanted me on Wegovy for prediabetes and weight loss, insurance denied it, and I wasn’t about to pay $1,700 a month out of pocket. That led me down the road of finding alternatives, which is how I ended up using a compounded version of tirzepatide.

Since then, I’ve had a lot of people ask the same question: what exactly is a compounding pharmacy, and how are they able to sell this stuff so much cheaper?

A compounding pharmacy is a licensed pharmacy that custom-makes medications for individual patients. Instead of a one-size-fits-all pen, they can adjust the dose, formulation, or delivery based on what a provider prescribes. This isn’t new—it’s actually how medicine used to be practiced before mass-produced drugs became the norm.

Back in the 1800s, you’d go to a doctor with a symptom, get a prescription, and then the pharmacist—sometimes the same person—would mix the medication right there. There was no one-size-fits-all dose. The dose was tailored to you.

In the case of GLP-1s like tirzepatide, that often means getting a vial instead of a preloaded pen, and drawing up your own dose with an insulin syringe.

That’s where the cost difference comes in. The brand-name versions—like Zepbound or Mounjaro made by Eli Lilly and Company—are patented, heavily marketed, and come with all the research, development, and delivery systems built in. You’re paying for all of that. Compounded versions don’t carry those same costs, so they’re often a fraction of the price.

In my case, I’m paying about $300 for a 50 mg vial. It comes with bacteriostatic water, syringes, and instructions. At lower doses, that can last more than a month. And instead of being locked into a preset weekly pen, I can adjust my dosing. If I’m doing well on a lower dose, I stay there. If I need to move up, I can. That flexibility has been one of the biggest benefits.

That flexibility also helps with side effects. If higher doses are causing symptoms like nausea, one option is to split the weekly dose—taking half at the beginning of the week and the other half a few days later. This avoids a large single dose, which can make it easier on your system. It also keeps the medication more steady in your body, so you don’t feel it wearing off toward the end of the week.

Another thing worth understanding is what this medication actually is. Tirzepatide is a peptide—a short chain of amino acids. The easiest way to think of peptides is like keys fitting into locks. Your body has receptors, and when the right peptide binds to the right receptor, it triggers a specific effect. In this case, tirzepatide targets GLP-1 and GIP receptors, helping regulate blood sugar, slow digestion, and reduce appetite. That’s why people lose weight on it, and often with relatively targeted effects.

Now, here’s where things get a little gray, and it’s important to be honest about it.

Some of these online sources don’t operate exactly like a traditional pharmacy. You’ll sometimes see language like “for research use only.” That’s there for legal and regulatory reasons. At the same time, it’s not hard to see why people are going this route. When something costs $1,700 through the traditional system and a few hundred dollars through an alternative channel, people are going to look for options.

But that also means there are trade-offs.

These products are not the same as FDA-approved, brand-name medications. They don’t go through the same level of oversight, and quality can vary depending on where you get them. You’re also taking on more responsibility—mixing the medication, measuring doses, and giving the injection correctly. That’s not nothing.

For some people, that level of involvement works. For others, it’s not a good fit.

I also had a friend who had been taking this for years before I ever started. That made it easier for me to consider. When she first told me about it, my thinking was pretty simple: You’ve been on it for years and you’re still here—it must be safe. It worked for you, so maybe it could work for me too.What I will say is this: people aren’t doing this because they want to play pharmacist. They’re doing it because they’re priced out of the system.

If insurance covered these medications, or if pricing made sense, most people would go through their doctor, pick it up at the pharmacy, and never think twice about it. Instead, people are left figuring it out on their own.

For me, and for a few friends, it’s worked. One of them is down 50 pounds and feels great. I’m losing weight, my appetite is under control, and I feel like I finally found something that works.

That’s why I wrote this follow-up—to explain what’s actually going on behind the scenes, what a compounding pharmacy is, and why more and more people are going this route.

It’s not perfect. But for a lot of people right now, it’s the only realistic option.

When Insurance Said No, I Found Another Way: How I Now Afford the Weight Loss Drug of My Choice

My doctor wanted me on a GLP-1—both to get my blood sugar down (I was prediabetic) and to help me lose weight. He prescribed Wegovy. My insurance denied it.

So I couldn’t get it. And paying out of pocket would have been around $1,700 a month.

A few months later, I learned about Trump Rx. I told my doctor I could get it for about $200 a month, and that got me started. But then during that first month I realized the catch—after a couple months, the price jumps to around $450. GoodRx and the deals on the pharma sites all work the same way.

That’s what got me looking for alternatives.

What I found is there are online options offering compounded versions of these medications. Instead of the expensive auto-injector pens, you get a vial, mix it with bacteriostatic water, and use a simple insulin syringe. Much cheaper.

A friend introduced me to the company and their website. I won’t share the name here, but if you want more information, you can email me using the link to the right.

Because I’m the one paying for it—and making the decision—I skipped Wegovy and went straight to tirzepatide—the medication behind Zepbound—for a fraction of the cost (not the brand name). I chose it because it targets two pathways—GLP-1 and GIP—and has been shown to help people lose more weight than semaglutide.

The cost is about $300 for a 50 mg vial. It comes with bacteriostatic solution, mixing syringes, and insulin syringes, along with instructions so you can prepare and use it properly.One vial can last more than a month, especially at lower doses, and you can control your dosing instead of being locked into a preset pen.

It’s nice. No doctor. No insurance. Simple. Easy. Inexpensive.

A couple things to be clear about:

• This is compounded, not brand-name
• It’s not exactly the same as what you get from the pharmacy
• You’re trading cost for convenience and tighter controls
• You need to know how to mix the medication, measure the dose, and give the injection properly
• You also need to understand dosing—what to take and when (or if) to increase

But because you’re essentially your own caregiver, you have some flexibility. For example, if the plan says to move up to a higher dose but I’m still losing weight on the current dose, I just stay where I am.

That’s the freedom of it.

But here’s the bigger issue:

People aren’t going this route because they want to. They’re doing it because they’re getting priced out.

If insurance covered these medications—or if pricing made sense—most people would just go through their doctor and pharmacy and be done with it.

Instead, people are left figuring it out on their own.

For my friends, this has worked great. One of them has lost 50 pounds and said, “I love this.” That’s how I was introduced to it—and so far, I’m losing and loving it too.

When BiPAP Works… and the Blood Gas Looks “Worse”

Here’s a scenario many respiratory therapists and clinicians have seen.

A chronic CO₂ retainer wears their BiPAP all night.
Morning labs come back.

And suddenly…

The pH is alkalemic.
The bicarbonate is higher.
The base excess is elevated.

At first glance, it looks confusing.
Shouldn’t the gas look better?

Actually — this is often a sign that BiPAP worked.

---

The Setup: Chronic CO₂ Retention

Many patients with:

• COPD
• Obesity hypoventilation syndrome
• Chronic respiratory failure

Live with chronically elevated CO₂.

For example:

• CO₂ in the 60–70 range
• pH near normal
• Elevated bicarbonate

How does the body tolerate this?

The kidneys compensate.

They retain bicarbonate to buffer the respiratory acidosis.
This is slow compensation — it takes days.

So over time, these patients develop:

• High CO₂
• High bicarbonate
• Near-normal pH

This becomes their baseline.

---

Then Comes a Good Night on BiPAP

The patient wears BiPAP consistently overnight.

Ventilation improves.
CO₂ is blown off more effectively.
Gas exchange improves.

But here’s the key:

The kidneys cannot adjust quickly.

Respiratory changes happen in minutes to hours.
Renal compensation takes 24–72 hours.

So what happens?

• CO₂ improves overnight
• Bicarbonate remains elevated
• pH rises

Result:

Metabolic alkalosis with alkalemic pH

---

It Looks Like This

Chronic respiratory acidosis (CO₂ ~63–65)
Renal compensation (chronically elevated bicarbonate)
Improved ventilation overnight with BiPAP
Kidneys can’t adjust quickly → bicarbonate stays high
Result → metabolic alkalosis / alkalemic pH

---

Why This Is Actually a Good Sign

When you see this pattern, it often means:

• The patient wore their BiPAP
• Ventilation improved
• The body is adjusting

In other words:

The therapy worked.

It may look worse on paper — but clinically, it's often reassuring.

---

A Common Clinical Pearl

Chronic CO₂ retainers often develop post-hypercapnic metabolic alkalosis when ventilation improves.

This happens:

• After BiPAP
• After intubation
• After improved ventilation
• After resolving respiratory failure

It’s not unusual.
And usually, it resolves gradually.

---

Why It Still Matters

Significant metabolic alkalosis can:

• Reduce respiratory drive
• Promote CO₂ retention later
• Make weaning more difficult

So it's worth:

• Monitoring
• Checking electrolytes
• Watching trends

But in most cases, it’s expected physiology — not a problem.

---

The Bottom Line

Sometimes when BiPAP works…
the blood gas looks “worse.”

But when you understand the physiology, it makes perfect sense.

And often, it’s actually a quiet sign of improvement.

The Stages of Respiratory Therapy Apathy

Stage 1: Innocence

You don’t know any better, so everything feels important.
A call comes from the ER and you drop whatever you’re doing — including your food — and rush down. STAT means stat. You walk fast. Sometimes you run. You feel needed.

---

Stage 2: Questioning

You start to notice things.
Why was this called stat? The patient looks fine. Why am I giving a breathing treatment to someone with a head cold? Is this pneumonia, or is she just wet?

You still do the work, but the questions start piling up.

---

Stage 3: Total Realization

At some point it hits you: a lot of what we do doesn’t change outcomes. Sometimes it just fills time. Sometimes it delays something else.

This lady doesn’t need it.

You do the treatment anyway — frustrated. An annoying patient really annoys you now. What burns you out isn’t just the work, it’s doing work that isn’t needed, over and over, until it piles up.

This is the stage where you try to educate. You explain to nurses. You explain to doctors. You go out of your way to say why it isn’t necessary.

And in the end, you do it anyway.

You realize you just wasted valuable time and training. You’ve been busy all day, finally sit down, and another treatment pops up. You feel it physically. Acceptance doesn’t arrive calmly — it arrives irritated.

---

Stage 4: Acceptance

You stop fighting reality. You understand the job for what it is. You may look at other careers. You may even daydream about leaving.

Then you realize leaving would mean more school, less money, or starting over.

So you stay.

You do what you’re told. You get it done. The anger fades, but it doesn’t completely disappear.

---

Stage 5: Selective Engagement

At this stage, you simply go into action.

You don’t blow up. You don’t complain — at least not much. You don’t argue anymore. You don’t try to change the course of treatment. You just do it, get it done, and go back to the RT cave.

You chill.

This is where experience finally turns into control. You don’t rush for everything anymore — you triage with your brain. You know when something actually matters and when it doesn’t. You still show up when it counts. You still advocate when it matters.

But you stop letting every unnecessary call hijack your nervous system.

You don’t care less.
You care more precisely.

And maybe that’s the part no one tells you:
apathy isn’t the end stage.

Clarity is.

Do Mucus-Clearing Treatments Really Work? A Look at the Evidence (and the Myths)

I’ve been a respiratory therapist for 28 years and 4 days. Hard to believe it’s been that long. I remember learning about hypertonic saline in RT school back in ’96. By the time I hit the floors in ’97, it was already out of style — “proven useless.”

Now?

It’s back with a vengeance. I see it ordered almost every day for… whatever disease of the week.

Same with CPT.

We used to pound on the chests of every post-op patient as if soreness alone was a mucus diagnosis. Eventually studies caught up and said, “yeah… this doesn’t actually do anything.” Plus, hitting fragile 85-year-old ribs? Maybe not our best era.

Mucomyst has always been the strange child. Ordered for people who “can’t bring up secretions,” or because a doctor thinks “it’ll help.” And of course the whole room ends up smelling like rotten eggs. The only people who don’t mind are the ones so old they don’t care about anything anymore — including their own room smelling like poop, as their comode sits filled in the corner.

And after this many years in the job, you learn the difference between:

something that actually works
and
something that looks like work.

Hypertonic saline. Pulmozyme. Mucomyst. The Vest. Acapella. CPT.

We’ve all done them. We’ve all questioned them.

Some days you walk into a patient’s room and they have everything ordered. If I actually did all of it by the book, I’d be in the room for two straight hours. No thanks. Nobody’s got that kind of time.

And eventually the question creeps in:

Does any of this actually help the patient?

Or are we just doing it because we've always done it?

So I dug through the research — real numbers, solid studies, repeatable results. Because one study is not science, guys. Science is when multiple studies show the same thing again and again — and even then, people still argue about it. That’s real science. And honestly, the reason we debate it is because only God knows the full truth — we’re just here trying to figure out our tiny piece of it.

Here’s what actually holds up.

---

CYSTIC FIBROSIS

The only place where mucus therapy truly delivers — even if the gains are smaller than you think.

Hypertonic Saline (3–7%)

• FEV₁ improves ~3%

• Exacerbations drop ~50%

• Good, repeatable evidence

• Helps clear mucus and improves sleep

Pulmozyme (Dornase Alfa)

• FEV₁ improves 5–12%

• Fewer infections

• Slows long-term decline

The Vest

• Works about the same as solid manual CPT

• FEV₁ improves 1–3%

• Reliable long-term airway clearance

Now here’s the part no one says out loud:

"If Pulmozyme improves FEV₁ 5–12%, that means, in 88–95% of patients, of lung function does not change.

CF is the condition where these therapies shine — and even there, the gains are modest.

Still worth it. Still life-extending. Just not magic.

---

BRONCHIECTASIS (Non-CF)

Helpful, but not groundbreaking.

OPEP Devices (Acapella, Aerobika, PEP)

• Patients feel less congested

• Increased sputum production

• FEV₁ improves 1–3% (which also means it does absolutely nothing in the other 97–99% of cases).

• Some studies show 10–20% fewer exacerbations (So in 80-90% of cases it has no effect)

The Vest

• Helps move mucus

• Patients feel better

• Minimal FEV₁ impact

Bottom line:
Therapies help people feel better and cough more effectively —
but they barely move the pulmonary function numbers.

---

THE VEST (General Use)

It looks dramatic. It sounds dramatic.
It helps the right patients — but it’s ordered for the wrong ones just as often.

Good for:

• CF

• Bronchiectasis

• Chronic heavy secretions

Not good for:

• Most COPD patients

• Pneumonia

• Mild secretions

• People who just “have rhonchi”

The Vest does not:

• Improve oxygenation

• Shorten hospital stays

A lot of doctors order it because it feels like “doing something.”
The evidence does not back that up for most inpatients.

---

COPD

The land where tradition rules over data.

Most COPD orders look like this:

• Mucomyst

• Acapella

• Light CPT

• Maybe the Vest (usually pointless)

Mucomyst (NAC Neb)

We all know it thins mucus.
But when you actually look at outcomes?

• No meaningful FEV₁ change

• No better oxygenation

• No reduction in hospitalizations

• Bronchospasm 10–20%

• Studies are old and weak

Translation:
Mucomyst for COPD is 90% tradition, 10% actual effect.

And the smell?
Rotten eggs. Every time.

Acapella / Aerobika

This actually does something.

• Helps mobilize mucus

• Patients feel better after using it

• FEV₁ changes 0–2%

• Some studies: 10–30% fewer COPD readmissions

Not a miracle — but useful.

The Vest (in COPD)

The research says:

• Helps the small handful of COPD patients with lots of mucus

• Does little to nothing for the majority

• No significant FEV₁ improvement

• No consistent length-of-stay improvement

80–90% of COPD patients get almost no benefit.

Yet it still gets ordered on autopilot.

---

PNEUMONIA

If we’re doing airway clearance here, we’re doing it for comfort — not cure.

Research shows:

• Chest PT does not cure pneumonia faster

• Vest does not improve oxygenation

• OPEP does not reduce mortality

• ACT does not reduce complications

• Does not shorten length of stay

The only tiny benefit?
A couple small studies suggest fever may break 12 hours sooner.

That’s it.

---

NEUROMUSCULAR & SPINAL CORD INJURY

Finally — a therapy that actually does exactly what it should.

CoughAssist / MIE

• Increases cough flow 50–150%

• Prevents mucus plugging

• Cuts pneumonia risk

• Reduces intubations

• Reduces hospitalizations

These patients don’t have a mucus problem —
they have a weak cough problem.

This device is a game-changer.

---

THE BOTTOM LINE

After almost three decades doing this job, this is the simplest way I can put it:

Some therapies help a lot.
Some help a little.
Some don’t help much at all.

But tradition sticks around forever.

And some days, when you’re dragging a Vest into the room of a COPD patient who hasn’t coughed anything up since 2003, you can feel the gap between what we know and what we’re ordered to do.

Here’s the honest breakdown:

STRONG EVIDENCE

• Pulmozyme (CF)

• Hypertonic saline (CF)

• CoughAssist (NMD, spinal injury)

MODERATE EVIDENCE

• Acapella / Aerobika

• OPEP for bronchiectasis

• The Vest for CF & bronchiectasis

WEAK EVIDENCE

• Mucomyst for COPD

• The Vest for COPD

• Chest PT for pneumonia

• OPEP for pneumonia

ALMOST NO EVIDENCE

• “We have to order something.”

I’m not trying to stir drama. I love respiratory care.
But I also like knowing the difference between what works and what’s just habit.

And honestly?

If a therapy only helps 10% of patients,
that means 90% of the time we’re basically doing busywork.
That’s not bad RT care — it’s just the reality of old habits in medicine.

And that’s why asking questions matters.

Giving Health Care Power Back to the People -- Fixing Obamacare

Why the ACA can stay — but the money should follow the consumer

The Affordable Care Act (Obamacare) has been around for over a decade now, and it’s not going anywhere. It’s helped millions of Americans gain access to health insurance who otherwise might not have had it. That’s a good thing — nobody should go without coverage in a country like ours.

But there’s something that’s never sat right about how the system works.

Right now, the government sends premium tax credits — money meant to help lower- and middle-income families afford insurance — directly to insurance companies. That means the government pays the companies first, and consumers just pick from what’s left on the shelf.

It’s a system that guarantees access — but not competition. And without competition, prices rarely go down.

---

What if the money followed the person?

Imagine a system where the same ACA tax credits go directly to you — not the insurance companies. You could still use those credits to buy insurance, but you’d decide where to spend them.

You’d be free to shop around, compare plans, and reward the companies that offer the best coverage for the best price.

In other words, you’d be the customer — not the middleman.

Insurance companies would have to compete for your business. They’d have to innovate, streamline, and actually lower premiums to attract you.

Competition is what drives every healthy market — and health care should be no different.

---

Keeping what works — fixing what doesn’t

We don’t have to scrap Obamacare to make this happen. The structure already exists:

• The tax credits are already there.

• The income limits and protections are already in place.

• People already use the Marketplace to compare plans.

The only change would be who gets the money first.

Right now, insurers get guaranteed payments — no matter how good or bad their service is. If consumers got the credit directly, those same companies would suddenly have a reason to earn it.

You could still choose from any approved plan. The government could still make sure everyone has access. The difference is that the power shifts from Washington and big insurers — to you.

---

Why this matters

Since the ACA passed, insurance companies have grown richer, not leaner. Health care costs haven’t gone down. Premiums keep climbing. And for many families, “affordable” coverage still means sky-high deductibles.

If the goal is affordable care, then we need real competition — not government-protected monopolies.

By giving consumers control of the credits, we’d see:

• More innovation among insurance companies.

• Transparent pricing and simpler plans.

• A stronger link between value and cost.

It’s the same logic that makes every other market work — when people control the money, businesses listen.

---

A simple, fair middle ground

We can keep the ACA, keep protections for people with preexisting conditions, and keep access open — all while making the system work for consumers, not just insurance companies.

Let the government fund health care, but let people choose where their dollars go.

If that sounds like common sense — it’s because it is.

Myth Buster: Don’t Panic Over One Frickin’ Study

Melatonin made headlines again this week—this time for supposedly increasing the risk of heart failure by 90 percent.

Cue the panic, the clickbait, and the sudden flood of patients ready to toss every bottle of sleep aid into the trash.

Let’s slow down.

Science Doesn’t Work on Panic

Real science isn’t built on a single data dump. It’s built on reproducibility—different teams, different patients, same results.
One study—no matter how big—only raises a question. It doesn’t answer it.

The research making the rounds came from an observational look at 130,000 people with insomnia.
The folks taking melatonin long-term seemed more likely to develop heart failure.
Interesting? Yes.
Proof? Nope.

They weren’t randomized.
They already had insomnia (a known heart-risk condition).
We don’t know their doses, their over-the-counter brands, or how accurate their medical coding was.

In other words, this study says, “Hey, we noticed something weird. Somebody should check this out.”
That’s how science starts—not how it ends.

---

How This Should Actually Change Behavior

If you pop melatonin occasionally to reset after night shifts or travel, this isn’t your cue to panic.
If you’ve been taking 10 mg every night for years, maybe talk with your doc about whether you still need it.
Use data as information, not as doom.

The smarter takeaway is balance:

• Don’t treat any supplement like candy.

• Don’t assume “natural” equals “harmless.”

• And don’t change meds or supplements because of a single headline.

---

What To Do Instead

• Talk to your provider before stopping or starting anything.

• Stay curious, not fearful. Ask why the data might look that way.

• Watch for follow-ups. If three or four future studies confirm the same link, then we have something real to chew on.

Until then, melatonin is still what it always was: a hormone your body already makes, sometimes helpful, sometimes over-used, rarely catastrophic.

---

Bottom Line

Don’t stop taking melatonin—or any medication—because of one frickin’ study.
Science isn’t a headline. It’s a process.

Breathe. Sleep. Question everything—but don’t overreact.book

I write this and I don't even take Melatonin. Still, I'm smart enough to know that one study is not science. People tried to pull that tone on us during Covid, where one study showed masked present COVID, whan all it showed was that it reduced your risk for COVID a few percentage points. Be careful what you read.